Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02810418

Enrollment

Registered

2016-06-23

Start date

2016-08-03

Completion date

2021-06-22

Last updated

2022-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Pancreatic Neoplasms

Keywords

Immunotoxin, Mesothelin, Antibody-based Therapeutics, Advanced Cancer

Brief summary

Background: LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by a very small number of normal tissues. Other cancers that make mesothelin include mesothelioma, cholangiocarcinoma, thymic carcinoma, ovarian, lung, gastric, endometrial, cervical, and ampullary cancers. After binding to the mesothelin on tumors, LMB-100 can attack and kill cancer cells. Researchers want to see how well it works when given with and without nab-paclitaxel, a drug which treats pancreatic cancer. Objectives: Arm A- To find a safe dose of LMB-100 with a fixed standard dose of nab-paclitaxel in people with advanced pancreatic cancer. To see how well the combination of the two drugs reduce tumor size. Arm B- To find a safe dose of LMB-100 when it is given as a continuous infusion over several days. Eligibility: Arm A- Adults age 18 and older with advanced pancreatic cancer that has worsened after anti-cancer therapy. Arm B- Adults age 18 and older with advanced pancreatic cancer, mesothelioma or other solid tumor that makes mesothelin that has worsened after anti-cancer therapy Design: Participants will be screened with medical history and physical exam. They will give blood, urine, and tissue samples. They will have scans and x-rays. During each 21-day cycle: * For Arm A * Participants will get LMB-100 by an intravenous (IV) catheter on days 1, 3, and 5. This is a tube inserted in a vein, usually in the arm. * Participants will get nab-paclitaxel by IV on days 1 and 8. * For Arm B * Participants will get LMB-100 by an IV catheter as a continuous infusion beginning on day 1 and continuing for 2-4 days * Some participants will also get nab-paclitaxel by IV on days 1 and 8. All participants will get this combination for up to 2 cycles or until their disease worsens or they have intolerable side effects. Participants will have blood and urine tests and scans throughout the study. Participants will have a safety follow-up visit 3-6 weeks after treatment ends. If their disease remains stable or improves, they will be scanned every 6 weeks until their disease gets worse. Even if their disease gets worse, they or their doctor will be called to talk about their cancer status....

Detailed description

Background: * Pancreatic cancer is the fourth most common cause of cancer death in the United States, claiming more than 40,000 lives each year. * Incidence nearly equals mortality with just 6% of participants living five years beyond their diagnosis. Most patients are diagnosed at an advanced stage, but even patients with early stage disease have a long term survival of less than 20%. * Mesothelin is specifically a marker of adenocarcinoma in the human disease and is not expressed in preceding pre-malignant stages of tumor development * Expression of mesothelin in pancreatic ductal adenocarcinoma (PDA) has been examined in several published studies and ranges from 86 to 100% * Recombinant immunotoxins (RITs) are antibody-based therapeutics that carry a toxin payload. RITs that target mesothelin contain a genetically engineered variant of Pseudomonas exotoxin A (PE) in which the native cell-binding domain of PE is replaced by the mesothelin-binding antibody fragment. SS1P was the first mesothelin-targeted RIT tested in patients. * LMB-100 contains a newly engineered PE fragment that has improved activity against most pancreatic cancer cell lines in vitro, and is also much less toxic than SS1P in preclinical models. The new PE contains modifications specifically designed to reduce immunogenicity of the molecule. * Pre-administration of paclitaxel with SS1P was demonstrated to increase the amount of immunotoxin internalized by tumor cells and to reduce levels of shed mesothelin in the intra-tumoral environment so that more immunotoxin could bind tumor cells. The effect is even more pronounced with NAB-paclitaxel in a pancreatic cancer model. * Initial clinical testing of LMB-100 was performed by Roche in a multi-center international first in human trial (NCT02317419). The agent was well tolerated and appeared to have decreased immunogenicity compared to SS1P based on preliminary results. * In initial and subsequent clinical testing, LMB-100 was found to have half-life of approximately 60 mins. This is shorter then that measured for previous RITs used in the clinical setting. Primary Objectives: * Arm A1 (Phase I, short infusion): --To determine the maximum tolerated dose of short infusion LMB-100 in combination nab-paclitaxel chemotherapy in participants with advanced pancreatic cancer * Arm B1(Continuous infusion single agent lead-in): --To determine the maximum tolerated dose of LMB-100 given in a continuous infusion format over 24 - 96 hours to patients with advanced solid tumors that express mesothelin * Arm B2 (Continuous infusion combination therapy) --Establish a tolerated dose of LMB-100 given by continuous infusion in combination with nab-paclitaxel chemotherapy in participants with advanced pancreatic cancer * Arm A2 (Phase II, short infusion): * To determine the objective response rate (Partial Response (PR)+Complete Response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria of short infusion LMB-100 in combination with nab-paclitaxel chemotherapy in participants with advanced pancreatic cancer Eligibility: * Age greater than or equal to18 years * Histologically confirmed recurrent, metastatic and/or advanced pancreatic ductal adenocarcinoma (Except for Arm B1 \[B Single Agent Lead-in\]) * For Arm B1 (Single Agent Lead-in), ONLY: Histologically confirmed solid tumor malignancy for which no curative therapy exists with at least 25% of tumor cells expressing mesothelin as determined by National Cancer Institute (NCI) Laboratory of Pathology. Determination can be made using archival tumor tissue or fresh biopsy. * Treatment must include at least one prior chemotherapy regimen * No nab-paclitaxel or paclitaxel treatment in the last four months (Except for Arm B1 \[Single Agent Lead-in\]) * Adequate organ function * Participants with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are eligible only for the Arm B1 (Single Agent Lead-in) Design: * This study is a Phase I/II open label study to assess the safety and efficacy of LMB-100 in combination with the standard of care agent nab-paclitaxel in participants metastatic and/or locally advanced pancreatic ductal adenocarcinoma * Subjects will be treated for up to 2 cycles * In Arm A1 (Phase I, short infusion) of the study, up to 3 dose levels will be evaluated. LMB-100 will be administered on days 1, 3 and 5 of a 21 day cycle and nab-paclitaxel will be administered on days 1 and 8 * Arm A2 (Phase II, short infusion), up to 20 evaluable participants (including those treated at the short infusion maximum tolerated dose (MTD) in the phase I study) will be enrolled. * Arm B1 (Continuous infusion single Agent Lead-in), escalating doses of single agent LMB-100 will be administered. The study drug will be given as a continuous infusion for the 1, 2, 3, or 4 days of a 21-day cycle. * Arm B2 (Continuous infusion, combination therapy) will be initiated after completion of both Arm A1 and Arm B1 Single Agent Lead-in. It will test a single dose level of LMB-100 based on data from the Lead-in given in combination with nab-paclitaxel. LMB-100 will be given as a continuous infusion for the 1, 2, 3 or 4 days of a 21-day cycle. Nabpaclitaxel will be given on Day 1 and Day 8. * The Arm A2 (Phase II, short infusion) portion of the study will be conducted in a Simon Minimax two stage phase II design. The first stage will enroll 13 evaluable participants, including the six participants treated at the short infusion MTD from phase I. If 1 or more has a response, then accrual would continue until a total of 20 evaluable participants have been enrolled.

Interventions

DRUGLMB-100

Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.

DRUGNab-Paclitaxel

Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles

DEVICEMesothelin Expression

Research blood test for Arm B1 eligibility

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: * For participants who will be receiving nab-paclitaxel (all arms except Phase I Arm B Single Agent Lead-in) * Histologically confirmed recurrent, advanced or metastatic pancreatic ductal adenocarcinoma as determined by National Cancer Institute (NCI) Laboratory of Pathology. * No treatment with paclitaxel or nab-paclitaxel within 4 months prior to initiation of study therapy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. * Adequate hematological function: neutrophil count of greater than or equal to 1.0 x 10(9) cells/L, platelet count of greater than or equal to 95,000/microliters, hemoglobin greater than or equal to 9 g/dL * Measurable disease as per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria v 1.1 * For participants who will NOT receive nab-paclitaxel (Arm B1 Single Agent Lead-in only) * Histologically confirmed solid tumor malignancy for which no curative therapy exists with at least 25% of tumor cells expressing mesothelin as determined by NCI Laboratory of Pathology. Determination can be made using archival tumor tissue or fresh biopsy. Subjects with epithelioid mesothelioma and pancreatic adenocarcinoma are automatically eligible and are not required to have this test. * ECOG performance status (PS) 0-2. * Adequate hematological function: neutrophil count of greater than or equal to 1.0 x 10(9) cells/L, platelet count of greater than or equal to 85,000/microliters, hemoglobin greater than or equal to 8.5 g/dL * Measurable and/or evaluable disease as per the RECIST Criteria v 1.1 * For all arms of the protocol * Participants must have received at least one prior chemotherapy regimen for their disease. * Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of LMB-100 in combination with nab-paclitaxel in persons \<18 years of age, children are excluded from this study. * Participants must be more than 14 days removed from most recent minor surgical procedure (such as biliary stenting), 28 days from most recent major surgical procedure, 14 days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be 72 hours or less and 28 days removed from last experimental drug treatment with unpublished or half-life greater than 72 hours. * All acute toxic effects of any prior radiotherapy, chemotherapy, experimental drug treatment or surgical procedure must have resolved to Grade less than or equal to 1, except alopecia (any grade) and peripheral neuropathy. * Serum albumin greater than or equal to 2.5 mg/dL without intravenous supplementation * Adequate liver function: Bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 x upper limit of normal (ULN). AST and ALT up to 5x ULN is permitted for patients with liver metastases. * Adequate renal function: creatinine clearance greater than or equal to 50 mL/min. * Must have left ventricular ejection fraction \> 50% * Must have an ambulatory oxygen saturation of \> 88% on room air * The effects of LMB-100 alone or in combination with nab-paclitaxel on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry until 3 months the last dose of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Ability of participant to understand and the willingness to sign a written informed consent document.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel	Approximately 6 weeks after the start of treatment and continuing every 6 weeks until progression or start of a new treatment, up to 1 year	OR is defined as partial responses + complete response in participants in the phase 2 Arm A portion of the study assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. Complete Response is a disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters
Maximum Tolerated Dose (MTD) of Short Infusion LMB-100 + Nab Paclitaxel	21 days after LMB-100 is administered (end of cycle 1)	MTD is defined as the highest dose tolerated without exceeding a pre-set number of adverse events in Phase 1, Arm A.
Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100	21 days after LMB-100 is administered (end of cycle 1)	MTD is defined as the highest dose tolerated without exceeding a pre-set number of adverse events in Phase 1, 1 Arm B, single agent lead-in

Secondary

Measure	Time frame	Description
Number of Participants With an Objective Response (OR) (Partial Responses + Complete Responses) in Phase 1 Arm A1	Approximately 6 weeks after the start of treatment and continuing every 6 weeks until progression or start of a new treatment up to 1 year.	OR is defined as partial response + complete response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. Complete Response is a disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters
Number of Participants With an Objective Response (OR) (Partial Response + Complete Response) in Phase 1, Arm B	Approximately 6 weeks after the start of treatment and continuing every 6 weeks until progression or start of a new treatment up to 1 year.	OR is defined as partial responses + complete response in participants in the phase 1 Arm B portion of the study assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. Complete Response is a disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.
Progression Free Survival (PFS)	Time from treatment initiation to disease progression or death, an average of 1 year.	PFS is the average time from treatment initiation to disease progression or death. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. And the appearance of one or more new lesions.
Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	Date treatment consent signed to date off study, approx. 11 mos, 8 days for A1DL1; 20 mos, 9 days for A1DL-1; 10 mos, 17 days for A2; 2 mos, 16 days for B1DL1; 14 mos, 30 days for B1DL2; 5 mos, 1 day for B2; and 4 mos, 15 days for B1DL3R.	Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Number of Participants With Adverse Events Attributed to LMB-100	Date treatment consent signed to date off study, approx. 11 mos, 8 days for A1DL1; 20 mos, 9 days for A1DL-1; 10 mos, 17 days for A2; 2 mos, 16 days for B1DL1; 14 mos, 30 days for B1DL2; 5 mos, 1 day for B2; and 4 mos, 15 days for B1DL3R.	Grade 1-4 adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 observed in subjects with pancreatic cancer. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe or medically significant. Grade 4 is life-threatening consequences.
Overall Survival (OS)	Time from treatment initiation to death, up to 1-2 years.	OS is the average time from treatment initiation to death.
Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	up to 3 months	DCR is the proportion of participants with stable disease, partial response or complete response at end of treatment. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other

Measure	Time frame	Description
Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1. Pre-dose and end of infusion (EOI) during Cycle 2 Day 1.	The maximum observed analyte concentration of dose was reported.
Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	First 28 days following infusion of LMB-100 on Cycle 1, Day 1 through the duration of the study treatment up to 1 year.	A DLT is defined per protocol as events attributed to LMB-100 and occurring during the DLT period such as hematological toxicities: Grade 4 neutropenia, Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, and Grade 3 thrombocytopenia associated with bleeding episodes. Grade ≥3 non-hematological toxicity with the exception of: Grade 3 nausea and vomiting without appropriate treatment, Grade 3 diarrhea lasting ≤2 days with no fever or dehydration, and isolated Grade 3 fever. Grade ≥4 non-hematological toxicity: infusion related reactions, and any other drug related toxicity qualified as a DLT per the discretion of the principal investigator.
Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1 Day 1. Pre-dose, end of loading dose and EOI during Cycle 2 Day 1.	The maximum observed analyte concentration in serum was reported.
Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUCinf)	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1.	Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0). It is used to characterize drug absorption.
Area Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUCinf)/D (Dose)	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1.	The AUC is a measure of the serum concentration of the drug dose over time. It is used to characterize drug absorption.
Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D	For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1 Day 1.	The AUC is a measure of the serum concentration of the drug dose over time. It is used to characterize drug absorption
Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100	For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1.	Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated to last measurement. It is used to characterize drug absorption.
The Total Clearance (CL) of LMB-100	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1.	The CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Plasma Half-Life (T1/2) of LMB-100	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1, Day 1.	Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.
Volume of Distribution (Vd) of LMB-100	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1, Day 1.	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2	For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day. Pre-dose and end of infusion (EOI) during Cycle 2 Day 1.	The maximum observed analyte concentration in serum was reported.
Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1 Day 1. Pre-dose, end of loading dose and EOI during Cycle 2 Day 1.	The maximum observed analyte concentration in serum was reported.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 Arm A1, DL1, Ph I Short Infusion 100µg/kg LMB-100 +125mg/m\^2 nab-paclitaxel LMB-100 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles;125mg/m\^2 Nab-Paclitaxel: Administered intravenously (IV) on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles	6
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100 Arm A1, DL-1, Ph I Short Infusion 65µg/kg LMB-100 +125mg/m\^2 nab-paclitaxel LMB-100 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles;125mg/m\^2 Nab-Paclitaxel: Administered intravenously (IV) on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles	8
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 Arm A2, Ph 2 Short Infusion 65µg/kg LMB-100 +125mg/m\^2 nab-paclitaxel LMB-100 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles;125mg/m\^2 Nab-Paclitaxel: Administered intravenously (IV) on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles	6
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in Arm B1, DL2, 48-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 (continuous infusion LMB-100 as a single agent): Administered intravenously (IV)for 48 hours continuously on the first 1 - 2 days of each 21 day cycle for a maximum of 2 cycles. A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.	6
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in Arm B1, DL1, 48-hr Continuous Infusion Single Agent Lead-in 65µg/kg/day LMB-100 (continuous infusion LMB-100 as a single agent): Administered IV for 48 hours continuously on the first 1 - 4 days of each 21 day cycle for a maximum of 2 cycles	3
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in Arm B1, DL3R, 24-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 (continuous infusion LMB-100 as a single agent): Administered IV for 24 hours continuously starting on days 1 and 4 of each 21 day cycle for a maximum of 2 cycles. A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.	6
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg Arm B2, 24-hr Continuous Infusion Combo Therapy 100µg/kg/day LMB-100+125mg/m\^ nab-paclitaxel Arms B2 (continuous infusion LMB-100): Administered intravenously (IV) for 24 hours continuously starting on day 1 of each 14 day cycle for a maximum of 3 cycles. A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.;125mg/m\^2 Nab-Paclitaxel: Administered intravenously (IV) on day 1of each 14 day cycle for a maximum of 3 cycles	5
Total	40

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG004	FG005
Arm A Dose Escalation	Adverse Event	2	1	0	0	0
Arm B Dose Escalation	Adverse Event	0	0	0	1	2
Dose Expansion	Adverse Event	0	1	1	0	0
Dose Expansion	Physician Decision	0	0	2	0	0

Baseline characteristics

Characteristic	Total	Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100	Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	15 Participants	0 Participants	3 Participants	4 Participants	2 Participants	0 Participants	3 Participants	3 Participants
Age, Categorical Between 18 and 65 years	25 Participants	6 Participants	5 Participants	2 Participants	4 Participants	3 Participants	3 Participants	2 Participants
Age, Continuous	61.0 years STANDARD_DEVIATION 10.6	54.5 years STANDARD_DEVIATION 7.6	61.0 years STANDARD_DEVIATION 7.7	69.9 years STANDARD_DEVIATION 8.5	47.0 years STANDARD_DEVIATION 12.5	59.2 years STANDARD_DEVIATION 12.3	62.8 years STANDARD_DEVIATION 7.9	66.8 years STANDARD_DEVIATION 10.4
Baseline CA 19-9 Patient 1	404.7 Unit/mL	404.7 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 10	10106 Unit/mL	0 Unit/mL	10106 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 11	13.2 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	13.2 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 12	25180 Unit/mL	0 Unit/mL	25180 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 13	14.8 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	14.8 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 14	911.3 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	911.3 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 15	88.4 Unit/mL	0 Unit/mL	88.4 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 16	284.7 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	284.7 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 17	302.6 Unit/mL	0 Unit/mL	302.6 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 18	4206 Unit/mL	0 Unit/mL	4206 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 19	93.7 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	93.7 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 2	10650 Unit/mL	10650 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 20	4482 Unit/mL	0 Unit/mL	4482 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 21	142.9 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	142.9 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 22	446.6 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	446.6 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 23	389.5 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	389.5 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 24	156.8 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	156.8 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 25	13348 Unit/mL	0 Unit/mL	13348 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 26	9254 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	9254 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 27	138.3 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	138.3 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 28	0.6 Unit/mL	0 Unit/mL	0.6 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 29	9571 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	9571 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 3	248800 Unit/mL	248800 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 30	2077 Unit/mL	0 Unit/mL	0 Unit/mL	2077 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 31	3424 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	3424 Unit/mL
Baseline CA 19-9 Patient 32	9326 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	9326 Unit/mL
Baseline CA 19-9 Patient 33	760 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	760 Unit/mL
Baseline CA 19-9 Patient 34	3297 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	3297 Unit/mL
Baseline CA 19-9 Patient 35	6345 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	6345 Unit/mL
Baseline CA 19-9 Patient 36	2966 Unit/mL	0 Unit/mL	0 Unit/mL	2966 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 37	99.8 Unit/mL	0 Unit/mL	0 Unit/mL	99.8 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 38	1340 Unit/mL	0 Unit/mL	0 Unit/mL	1340 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 39	31440 Unit/mL	0 Unit/mL	0 Unit/mL	31440 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 4	27.8 Unit/mL	27.8 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 40	3857 Unit/mL	0 Unit/mL	0 Unit/mL	3857 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 5	7081 Unit/mL	7081 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 6	123 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	123 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 7	1277 Unit/mL	1277 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 8	94210 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	94210 Unit/mL	0 Unit/mL	0 Unit/mL
Baseline CA 19-9 Patient 9	1500 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	0 Unit/mL	1500 Unit/mL	0 Unit/mL	0 Unit/mL
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	36 Participants	6 Participants	8 Participants	5 Participants	6 Participants	3 Participants	6 Participants	2 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	4 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	3 Participants
Number of Participants with Prior Therapies Prior nab-paclitaxel	20 Participants	1 Participants	3 Participants	2 Participants	5 Participants	1 Participants	5 Participants	3 Participants
Number of Participants with Prior Therapies Radiation	26 Participants	5 Participants	4 Participants	5 Participants	4 Participants	2 Participants	2 Participants	4 Participants
Number of Participants with Prior Therapies Whipple	20 Participants	2 Participants	5 Participants	4 Participants	2 Participants	1 Participants	3 Participants	3 Participants
Number of Participants with Sites of Disease Ascites	8 Participants	1 Participants	0 Participants	2 Participants	2 Participants	1 Participants	2 Participants	0 Participants
Number of Participants with Sites of Disease Liver	24 Participants	4 Participants	5 Participants	4 Participants	3 Participants	3 Participants	4 Participants	1 Participants
Number of Participants with Sites of Disease Lung	23 Participants	2 Participants	5 Participants	4 Participants	3 Participants	3 Participants	3 Participants	3 Participants
Number of Participants with Sites of Disease Other	25 Participants	2 Participants	3 Participants	6 Participants	5 Participants	3 Participants	3 Participants	3 Participants
Participants Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0	14 Participants	2 Participants	4 Participants	3 Participants	2 Participants	0 Participants	1 Participants	2 Participants
Participants Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 1	24 Participants	4 Participants	4 Participants	3 Participants	4 Participants	1 Participants	5 Participants	3 Participants
Participants Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 2	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Participants Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Unknown	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	3 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Race (NIH/OMB) Black or African American	4 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	1 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) White	32 Participants	6 Participants	7 Participants	6 Participants	4 Participants	1 Participants	4 Participants	4 Participants
Region of Enrollment United States	40 participants	6 participants	8 participants	6 participants	6 participants	3 participants	6 participants	5 participants
Sex: Female, Male Female	18 Participants	2 Participants	4 Participants	4 Participants	2 Participants	2 Participants	1 Participants	3 Participants
Sex: Female, Male Male	22 Participants	4 Participants	4 Participants	2 Participants	4 Participants	1 Participants	5 Participants	2 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk
deaths Total, all-cause mortality	5 / 6	8 / 8	5 / 6	6 / 6	3 / 3	6 / 6	3 / 5
other Total, other adverse events	6 / 6	8 / 8	6 / 6	6 / 6	3 / 3	6 / 6	5 / 5
serious Total, serious adverse events	3 / 6	4 / 8	1 / 6	2 / 6	2 / 3	2 / 6	1 / 5

Outcome results

Primary

Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100

MTD is defined as the highest dose tolerated without exceeding a pre-set number of adverse events in Phase 1, 1 Arm B, single agent lead-in

Time frame: 21 days after LMB-100 is administered (end of cycle 1)

Population: Arm B2, Phase I, 24-hour continuous infusion combination therapy is not reported here because MTD was only assessed in the Phase I, Arm B single agent lead-in Arm/Groups.~Please note: Dose 100 (µg/kg/day), for duration (24 Hours), schedule Days 1 \& 4, preceded by a 40 mcg/kg loading dose over 30 minutes, was determined to be the preferred schedule.

Arm	Measure	Value (NUMBER)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100	100 Dose (µg/kg)

Primary

Maximum Tolerated Dose (MTD) of Short Infusion LMB-100 + Nab Paclitaxel

MTD is defined as the highest dose tolerated without exceeding a pre-set number of adverse events in Phase 1, Arm A.

Time frame: 21 days after LMB-100 is administered (end of cycle 1)

Arm	Measure	Value (NUMBER)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Tolerated Dose (MTD) of Short Infusion LMB-100 + Nab Paclitaxel	65 µg/kg

Primary

Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel

OR is defined as partial responses + complete response in participants in the phase 2 Arm A portion of the study assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. Complete Response is a disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters

Time frame: Approximately 6 weeks after the start of treatment and continuing every 6 weeks until progression or start of a new treatment, up to 1 year

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel	1 Participants

Secondary

Number of Participants With Adverse Events Attributed to LMB-100

Grade 1-4 adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 observed in subjects with pancreatic cancer. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe or medically significant. Grade 4 is life-threatening consequences.

Time frame: Date treatment consent signed to date off study, approx. 11 mos, 8 days for A1DL1; 20 mos, 9 days for A1DL-1; 10 mos, 17 days for A2; 2 mos, 16 days for B1DL1; 14 mos, 30 days for B1DL2; 5 mos, 1 day for B2; and 4 mos, 15 days for B1DL3R.

Population: No B2 grade 1, 3, and 4; B1 DL1 grade 1, 3, and 4; B1 DL2 grade 1; and B1 DL3R grade 1, 3, and 4 adverse events.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	4 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	4 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Edema	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	4 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	3 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	2 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Fever	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	2 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	3 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	2 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Edema	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	6 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	3 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Fever	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	1 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	2 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	1 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	1 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	2 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	1 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	4 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	7 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	2 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	2 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	6 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	2 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	2 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	4 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	4 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	5 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Chills	1 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Fever	3 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Edema	6 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	4 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	6 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Chills	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Edema	2 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	2 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	7 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Fever	2 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	2 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Cough	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Edema	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	1 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	1 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	1 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	1 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	1 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	1 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Edema	3 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	4 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm A2, Phase 2 Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	3 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	1 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	3 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	2 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	1 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	2 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	6 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	1 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	2 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	2 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	1 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Edema	4 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	1 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	1 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm A2, Phase 2 Grade 1	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	1 Participants
Arm A2, Phase 2 Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	1 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	1 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	1 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm A2, Phase 2 Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	1 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	1 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Edema	4 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	1 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	1 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	2 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fever	1 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	1 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	3 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	3 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	2 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	1 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	1 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 3	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	1 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 2 Phase I Grade 4	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	2 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	1 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fever	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm B1, Dose Level 1 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	4 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fever	1 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	1 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B1, Dose Level 3R Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Tachycardia	1 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	GI disturbances	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Decreased urine output	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dehydration	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ascites	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dizziness	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoalbuminemia	2 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pericardial effusion	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypoxia	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Rash and pruritis	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypotension	2 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Proteinuria	1 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fever	1 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Generalized pain	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Edema	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Creatinine increased	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Acute kidney injury	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Atrial fibrillation	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleural effusion	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Elevated LFT's	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Lymphocyte count decreased	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Chills	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Infusion-related reactions	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pleuritic pain	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anemia	1 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Ventricular dysfunction	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypocalcemia	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Anorexia	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hypophosphatemia	1 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Pulmonary edema	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Nausea and vomiting	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Fatigue	2 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Allergic reaction	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Cough	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Myalgia	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Weight gain	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Electrolyte disturbances	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Hyponatremia	0 Participants
Arm B2 Phase I Grade 2	Number of Participants With Adverse Events Attributed to LMB-100	Dyspnea	0 Participants

Secondary

Number of Participants With an Objective Response (OR) (Partial Response + Complete Response) in Phase 1, Arm B

OR is defined as partial responses + complete response in participants in the phase 1 Arm B portion of the study assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. Complete Response is a disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame: Approximately 6 weeks after the start of treatment and continuing every 6 weeks until progression or start of a new treatment up to 1 year.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With an Objective Response (OR) (Partial Response + Complete Response) in Phase 1, Arm B	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With an Objective Response (OR) (Partial Response + Complete Response) in Phase 1, Arm B	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With an Objective Response (OR) (Partial Response + Complete Response) in Phase 1, Arm B	0 Participants

Secondary

Number of Participants With an Objective Response (OR) (Partial Responses + Complete Responses) in Phase 1 Arm A1

OR is defined as partial response + complete response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. Complete Response is a disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters

Time frame: Approximately 6 weeks after the start of treatment and continuing every 6 weeks until progression or start of a new treatment up to 1 year.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With an Objective Response (OR) (Partial Responses + Complete Responses) in Phase 1 Arm A1	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With an Objective Response (OR) (Partial Responses + Complete Responses) in Phase 1 Arm A1	1 Participants

Secondary

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	6 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	8 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	6 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	6 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	3 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	6 Participants
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).	5 Participants

Secondary

Overall Survival (OS)

OS is the average time from treatment initiation to death.

Time frame: Time from treatment initiation to death, up to 1-2 years.

Population: Arm/Groups A1 and B1 are not separated per Arm/Group because the breakdown by individual treatment group within each arm results in numbers that are so small that the data becomes virtually useless. Patients enrolled in A1 who were treated at the maximum tolerated dose (MTD) and meet the eligibility requirement for A2 are also counted toward the A2 endpoints as per protocol.

Arm	Measure	Value (MEDIAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Overall Survival (OS)	202 Days	Standard Deviation 332
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Overall Survival (OS)	160 Days	Standard Deviation 196
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Overall Survival (OS)	89 Days	Standard Deviation 124
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Overall Survival (OS)	167 Days	Standard Deviation 348

Secondary

Progression Free Survival (PFS)

PFS is the average time from treatment initiation to disease progression or death. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. And the appearance of one or more new lesions.

Time frame: Time from treatment initiation to disease progression or death, an average of 1 year.

Population: It was specified in the protocol that patients enrolled in Arm A1 who received the maximum tolerated dose (MTD) should be included for PFS endpoint analysis of Arm A2 data. Therefore, 8 (Arm A1, DL-1) + 6 (Arm A2) = 14 patients were included in the Arm 2 PFS analysis.

Arm	Measure	Value (MEDIAN)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Progression Free Survival (PFS)	NA Months
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Progression Free Survival (PFS)	NA Months
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Progression Free Survival (PFS)	NA Months
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Progression Free Survival (PFS)	NA Months
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Progression Free Survival (PFS)	NA Months
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Progression Free Survival (PFS)	NA Months
Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg	Progression Free Survival (PFS)	NA Months

Secondary

Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)

DCR is the proportion of participants with stable disease, partial response or complete response at end of treatment. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Time frame: up to 3 months

Population: It was planned that this outcome measure would be reported by Arm and not by individual dose levels within each arm. Pts enrolled in A1 who were treated at the max.tolerated dose and meet the eligibility requirement for A2 are also counted toward the A2 endpoints as per protocol. We are unable to calculate DCR at 4 mos because many pts with stable disease immediately went on to receive other therapies following completion of scheduled 2-3 cycles of LMB-100. Therefore,we are reporting DCR at EOT.

Arm	Measure	Group	Value (NUMBER)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Progressive Disease	0.21 Proportion of participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Complete Response	0 Proportion of participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Not Evaluable	0 Proportion of participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Stable Disease	0.71 Proportion of participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Partial Response	0.07 Proportion of participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Stable Disease	0.5 Proportion of participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Progressive Disease	0.36 Proportion of participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Not Evaluable	0.07 Proportion of participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Complete Response	0 Proportion of participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Partial Response	0.07 Proportion of participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Stable Disease	0.27 Proportion of participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Partial Response	0 Proportion of participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Complete Response	0 Proportion of participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Progressive Disease	0.60 Proportion of participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Not Evaluable	0.13 Proportion of participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Progressive Disease	2 Proportion of participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Complete Response	0 Proportion of participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Partial Response	0 Proportion of participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Stable Disease	0.4 Proportion of participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)	Not Evaluable	1 Proportion of participants

Other Pre-specified

Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUCinf)

Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0). It is used to characterize drug absorption.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1.

Population: Extended serum drug concentrations are available for all participants during Cycle 1. During Cycle 2, these bloods were not drawn (per protocol) after the first few participants on study, therefore elimination rate and AUC could only be calculated for Cycle 1 in most patients. Results from all participants receiving 65 mcg/kg short infusion were combined for the pharmacokinetic analysis as all received the same dose of LMB-100.

Arm	Measure	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUCinf)	2,550 h*ng/mL	Standard Deviation 38.2
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUCinf)	1,409 h*ng/mL	Standard Deviation 47.9

Other Pre-specified

Area Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUCinf)/D (Dose)

The AUC is a measure of the serum concentration of the drug dose over time. It is used to characterize drug absorption.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1.

Arm	Measure	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Area Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUCinf)/D (Dose)	415 H*ng/mL/mg	Standard Deviation 56.5
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Area Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUCinf)/D (Dose)	315 H*ng/mL/mg	Standard Deviation 45.8

Other Pre-specified

Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D

The AUC is a measure of the serum concentration of the drug dose over time. It is used to characterize drug absorption

Time frame: For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1 Day 1.

Population: Extended serum drug concentrations are avail. for all participants during C1. During C2, these bloods were not drawn (per protocol) after the first few participants on study, therefore elimination rate \& AUC could only be calculated for C1 in most pts. AUClast is reported for Arms B1 and B2 as the measurements taken do not permit calculation of AUCinf.

Arm	Measure	Value (MEDIAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D	519 h*ng/ml/mg	Standard Deviation 604
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D	229 h*ng/ml/mg	Standard Deviation 71
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D	233 h*ng/ml/mg	Standard Deviation 64
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D	288 h*ng/ml/mg	Standard Deviation 184

Other Pre-specified

Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2

The maximum observed analyte concentration of dose was reported.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1. Pre-dose and end of infusion (EOI) during Cycle 2 Day 1.

Population: LMB-100 peak plasma concentrations were available for all patients treated on study. Results from all participants receiving 65 mcg/kg short infusion (Arms A1 \& A2) were combined for the pharmacokinetic analysis as all received the same dose of LMB-100.

Arm	Measure	Group	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2	Cycle 1 Day 1	197 ng/mL/mg	Standard Deviation 18.5
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2	Cycle 2 Day 1	181 ng/mL/mg	—
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2	Cycle 1 Day 1	188 ng/mL/mg	Standard Deviation 77.7
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2	Cycle 2 Day 1	158 ng/mL/mg	Standard Deviation 51.9

Other Pre-specified

Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2

The maximum observed analyte concentration in serum was reported.

Time frame: For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1 Day 1. Pre-dose, end of loading dose and EOI during Cycle 2 Day 1.

Population: LMB-100 peak plasma concentrations were available for all patients treated on study. The Cmax reported for Arms B1 DL2 and DL3R and for Arm B2 occurred at end of the loading dose. Only non-zero values are reported for two participants in Cycle 2.

Arm	Measure	Group	Value (MEDIAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	235 ng/mL	Standard Deviation 398
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	26.3 ng/mL	Standard Deviation 12.1
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	Cycle 2 Day 1	20.8 ng/mL	—
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	45.1 ng/mL	Standard Deviation 18.5
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	34.5 ng/mL	Standard Deviation 19.8
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2	Cycle 2 Day 1	10.5 ng/mL	Standard Deviation 5.9

Other Pre-specified

Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2

The maximum observed analyte concentration in serum was reported.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day. Pre-dose and end of infusion (EOI) during Cycle 2 Day 1.

Arm	Measure	Group	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2	Cycle 1 Day 1	1,282 ng/mL	Standard Deviation 14.9
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2	Cycle 2 Day 1	1,306 ng/mL	—
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2	Cycle 1 Day 1	858.9 ng/mL	Standard Deviation 43
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2	Cycle 2 Day 1	748 ng/mL	Standard Deviation 58.1

Other Pre-specified

Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2

The maximum observed analyte concentration in serum was reported.

Arm	Measure	Group	Value (MEDIAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	1124 ng/mL	Standard Deviation 1892
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	Cycle 2 Day 1	371 ng/mL	—
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	488 ng/mL	Standard Deviation 270
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	485 ng/mL	Standard Deviation 154
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	Cycle 1 Day 1	307 ng/mL	Standard Deviation 163
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2	Cycle 2 Day 1	195 ng/mL	Standard Deviation 248

Other Pre-specified

Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)

A DLT is defined per protocol as events attributed to LMB-100 and occurring during the DLT period such as hematological toxicities: Grade 4 neutropenia, Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, and Grade 3 thrombocytopenia associated with bleeding episodes. Grade ≥3 non-hematological toxicity with the exception of: Grade 3 nausea and vomiting without appropriate treatment, Grade 3 diarrhea lasting ≤2 days with no fever or dehydration, and isolated Grade 3 fever. Grade ≥4 non-hematological toxicity: infusion related reactions, and any other drug related toxicity qualified as a DLT per the discretion of the principal investigator.

Time frame: First 28 days following infusion of LMB-100 on Cycle 1, Day 1 through the duration of the study treatment up to 1 year.

Population: Arm A2 Phase 2 is not shown because it is not applicable due to dose expansion.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Edema	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Urine output decreased	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Fatigue	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 1 creatinine increase	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Hypotension	1 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 proteinuria	0 Participants
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Myalgia	2 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Fatigue	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Myalgia	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Hypotension	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Urine output decreased	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Edema	1 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 1 creatinine increase	0 Participants
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 proteinuria	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Hypotension	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Fatigue	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Edema	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Urine output decreased	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 proteinuria	1 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Myalgia	0 Participants
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 1 creatinine increase	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Myalgia	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Edema	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Fatigue	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Hypotension	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Urine output decreased	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 proteinuria	0 Participants
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 1 creatinine increase	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Hypotension	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Fatigue	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 1 creatinine increase	1 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Edema	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 proteinuria	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Myalgia	0 Participants
Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Urine output decreased	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 1 creatinine increase	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Urine output decreased	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Hypotension	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Fatigue	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 proteinuria	0 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Edema	1 Participants
Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)	Grade 3 Myalgia	0 Participants

Other Pre-specified

Plasma Half-Life (T1/2) of LMB-100

Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1, Day 1.

Population: LMB100 plasma conc. avail. for 20 pts on Arms A1/A2. Extended plasma drug conc. avail. for all pts during C1. During C2, these bloods were not drawn (per protocol) after1st few pts on study; elimination rate \& T1/2 could only be calc. for C1 in most pts. Results from all pts w/65 mcg/kg short infusion were combined for the pharmacokinetic analysis (all rec'd same dose LMB-100). Arms B1/B2 calc. of T1/2 was not planned \& plasma sample time points were inappropriate for computing this measure.

Arm	Measure	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Plasma Half-Life (T1/2) of LMB-100	1.25 hour(h)	Standard Deviation 53.9
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Plasma Half-Life (T1/2) of LMB-100	0.99 hour(h)	Standard Deviation 12.9

Other Pre-specified

The Total Clearance (CL) of LMB-100

The CL is a quantitative measure of the rate at which a drug substance is removed from the body.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1 Day 1.

Arm	Measure	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	The Total Clearance (CL) of LMB-100	2.97 L/h	Standard Deviation 44.3
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	The Total Clearance (CL) of LMB-100	4.98 L/h	Standard Deviation 116

Other Pre-specified

Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100

Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated to last measurement. It is used to characterize drug absorption.

Time frame: For Arms B1 & B2: Pre-dose, end of loading dose, 2 and 6 hours after start of continuous infusion, end of infusion (EOI) and 2 hrs after EOI during Cycle 1.

Population: Extended serum drug concentrations are avail. for all participants during C1. During C2, these bloods were not drawn (per protocol) after the first few participants on study, therefore elimination rate \&AUC could only be calculated for C1 in most pts. AUClast is reported for Arms B1 and B2 as the measurements taken do not permit calculation of AUCinf.

Arm	Measure	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100	2671 h*ng/ml	Standard Deviation 2778
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100	4148 h*ng/ml	Standard Deviation 1746
Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100	2508 h*ng/ml	Standard Deviation 388
Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in	Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100	2417 h*ng/ml	Standard Deviation 1006

Other Pre-specified

Volume of Distribution (Vd) of LMB-100

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame: For Arms A1 & A2: Pre-dose, end of infusion (EOI), 1, 2 and 4 hours after EOI during Cycle 1, Day 1.

Arm	Measure	Value (MEAN)	Dispersion
All Participants in Arm A1 DL-1 and Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100	Volume of Distribution (Vd) of LMB-100	4.91 L	Standard Deviation 20.5
Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100	Volume of Distribution (Vd) of LMB-100	7.48 L	Standard Deviation 106

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100

Maximum Tolerated Dose (MTD) of Short Infusion LMB-100 + Nab Paclitaxel

Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel

Number of Participants With Adverse Events Attributed to LMB-100

Number of Participants With an Objective Response (OR) (Partial Response + Complete Response) in Phase 1, Arm B

Number of Participants With an Objective Response (OR) (Partial Responses + Complete Responses) in Phase 1 Arm A1

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).

Overall Survival (OS)

Progression Free Survival (PFS)

Proportion of Participants Disease Control Rate (DCR) at End of Treatment (EOT)

Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUCinf)

Area Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUCinf)/D (Dose)

Area Under the Serum Concentration Versus Time Curve Extrapolated to Last Measurement (AUClast)/D

Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm A1 and Arm A2

Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2

Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm A1 and Arm A2

Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100 in Arm B1 and Arm B2

Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)

Plasma Half-Life (T1/2) of LMB-100

The Total Clearance (CL) of LMB-100

Time Curve Extrapolated to Last Measurement (AUClast) for LMB-100

Volume of Distribution (Vd) of LMB-100